# Phase 3 Open-Label Controlled Trial of Convalescent Plasma in Early COVID-19 Infection

> **NCT06084351** · PHASE3 · WITHDRAWN · sponsor: **Larkin Community Hospital**

## Conditions studied

- Covid19

## Interventions

- **DRUG:** Convalescent Plasma
- **OTHER:** Standard of Care

## Key facts

- **NCT ID:** NCT06084351
- **Lead sponsor:** Larkin Community Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-05-12
- **Primary completion:** 2020-10-30
- **Final completion:** 2020-10-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study Period Ended / Not Completed
- **Last updated:** 2023-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06084351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06084351, "Phase 3 Open-Label Controlled Trial of Convalescent Plasma in Early COVID-19 Infection". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT06084351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*